Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 6, 2006, Pages 2214-2217

  Takebayashi, Kohzo ^a   Matsumoto, Sachiko ^a   Aso, Yoshimasa ^a   Inukai, Toshihiko ^a  

^a DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ALDOSTERONE; AMLODIPINE; CHEMOATTRACTANT; CYSTEINE; MONOCYTE CHEMOTACTIC PROTEIN 1; SPIRONOLACTONE; SYNAPSIN I;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE COURSE; DRUG EFFECT; DRUG INHIBITION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ALDOSTERONE ANTAGONISTS; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DINOPROST; HUMANS; OXIDATIVE STRESS; SPIRONOLACTONE;

EID: 33744954417     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1718     Document Type: Article

References (20)

1. Chen S, Wolf G, Ziyadeh FN 2001 The rennin-angiotensin system in diabetic nephropathy. Contrib Nephrol 135:212-221
2. Wolf G, Ziyadeth FN 1997 The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanism. Am J Kidney Dis 29:153-163
3. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL 2002 Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40:504-510
4. Rocha R, Stier Jr CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK 2000 Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141:3871-3878
5. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT 2002 Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161:1773-1781
6. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M 2004 Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin- converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109:2213-2220
7. Amann B, Tinzmann R, Angelkort B ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 26:2421-2425
8. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM 1998 Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 83:952-959
9. Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T, Inoue N, Hirata K, Matsukawa A, Morishita R, Kaneda Y, Yokoyama M 2002 Local over expression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. Arterioscler Thromb Vasc Biol 22:115-120
10. Wada T, Fruichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda S, Takasawa K, Yoshimura M, Kida H, Kobayashi K, Mukaida N, Naito T, Matsushima K, Yokoyama H 2000 Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 58:1492-1499
11. Schlondorff D, Nelson PJ, Luckow B, Banas B 1997 Chemokines and renal disease. Kidney Int 51:610-621
12. Patrono C, Fitzgerald GA 1997 Isoprostanes: potential markers of oxidative stress in arterothrombotic disease. Arterioscler Thromb Vasc Biol 17:2309-2315
13. Reilly MP, Pratico D, Delanty N, DiMinno G, Ttrmoli E, Rader D, Kapoor S, Rokach J, Lawson J, FitzGerald GA 1998 Increased formation of distinct F2α isoprostanes in hypercholesterolemia. Circulation 98:2822-2828
14. American Diabetes Association 1999 Diabetic nephropathy. Diabetes Care 22:S66
15. 2-isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot Essent Fatty Acids 61:203-205
16. Ushio-Funaki M, Zafari AM, Fukui T, Ishizaka N, Griendling KK 1996 p22phox is a critical component of the superoxide-generating NAD/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271:23317-23321
17. Pitt B 1995 "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 9:145-149
18. Blasi ER, Rocha R, Rudolph AM, Blomme EAG, Polly ML, McMahon EG 2003 Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63:1791-1800
19. Nishiyama A, Yao L, Nagai Y, Miyata K, Yosjizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y 2004 Possible contribution of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rat. Hypertension 43:841-848
20. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, Ravid M 2004 The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 21:471-474